Details for Patent: 9,593,098

Which drugs does patent 9,593,098 protect, and when does it expire?

Patent 9,593,098 protects LAZCLUZE and is included in one NDA.

This patent has fifty-seven patent family members in twenty-four countries.

Summary for Patent: 9,593,098

Title:	Compounds and compositions for modulating EGFR mutant kinase activities
Abstract:	The present invention provides a new group of protein kinase inhibitors, aminopyrimidine derivatives, and pharmaceutically acceptable salts thereof that are useful for treating cell proliferative disease and disorder such as cancer and immune disease. The present invention provides methods for synthesizing and administering the protein kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the protein kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefore. The invention also provides useful intermediates generated during the syntheses of the aminopyrimidine derivatives.
Inventor(s):	Byung-Chul Suh, Paresh Devidas Salgaonkar, Jaekyoo Lee, Jong Sung Koh, Ho-Juhn Song, In Yong Lee, Jaesang LEE, Dong Sik Jung, Jung-Ho Kim, Se-Won Kim
Assignee:	Yuhan Corp
Application Number:	US14/881,930
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 9,593,098

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Janssen Biotech	LAZCLUZE	lazertinib mesylate	TABLET;ORAL	219008-001	Aug 19, 2024		RX	Yes	No			Y	Y		FIRST-LINE TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EGFR EXON 19 DELETIONS OR EXON 21 L858R SUBSTITUTION MUTATIONS, IN COMBINATION WITH AMIVANTAMAB
Janssen Biotech	LAZCLUZE	lazertinib mesylate	TABLET;ORAL	219008-002	Aug 19, 2024		RX	Yes	Yes			Y	Y		FIRST-LINE TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EGFR EXON 19 DELETIONS OR EXON 21 L858R SUBSTITUTION MUTATIONS, IN COMBINATION WITH AMIVANTAMAB

International Family Members for US Patent 9,593,098

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2015331166
Brazil	112017007769
Canada	2962914
China	106795144
China	111686110